Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlitinib plus capecitabine in advanced or metastatic biliary tract cancer
CTR20171140Phase 2Terminated
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varlitinib in biliary cancer, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer, Ampullary cancer (AC), sponsored by ASLAN Pharmaceuticals. Started Dec 2017; status: terminated.
02
Drugs
varlitinib
03
Conditions
biliary cancerintrahepatic cholangiocarcinoma (ICC)extrahepatic cholangiocarcinoma (eCCA)gallbladder cancerAmpullary cancer (AC)
Beyond the preview
Go deeper on CTR20171140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171140.